New Two-Pronged cell therapy tested for tough blood cancer
NCT ID NCT07249073
Summary
This is an early-stage study to test the safety and find the right dose of a new type of CAR-T cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy, called CAR19-BCMA, is designed to attack cancer cells in two ways. Researchers will enroll a small group of patients to monitor for side effects and see if the treatment shows early signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.